Cite
Morris KA, Golding JF, Axon PR, et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract. 2016;3(4):281-289doi: 10.1093/nop/npv065.
Morris, K. A., Golding, J. F., Axon, P. R., Afridi, S., Blesing, C., Ferner, R. E., Halliday, D., Jena, R., Pretorius, P. M., Evans, D. G., McCabe, M. G., & Parry, A. (2016). Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-oncology practice, 3(4), 281-289. https://doi.org/10.1093/nop/npv065
Morris, Katrina A, et al. "Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation." Neuro-oncology practice vol. 3,4 (2016): 281-289. doi: https://doi.org/10.1093/nop/npv065
Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM, Evans DG, McCabe MG, Parry A. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract. 2016 Dec;3(4):281-289. doi: 10.1093/nop/npv065. Epub 2016 Jan 07. PMID: 29692918; PMCID: PMC5909937.
Copy
Download .nbib